An early phase study of an EGFRvIII peptide based vaccine in patients with EGFRvIII expressing cancers.
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Hemocyanin; Rindopepimut; Sargramostim
- Indications Gastric cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions
- 20 Jul 2012 Actual end date (November 2008) added as reported by ClinicalTrials.gov record.
- 04 Nov 2005 New trial record.